A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

NCT04850040 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Resectable

Interventions

DRUG: Apatinib Mesylate
DRUG: Camrelizumab
DRUG: Oxaliplatin

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences